Skip to main content
Clinical Trials/NCT02532790
NCT02532790
Unknown
Phase 2

The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children

Nanjing Children's Hospital1 site in 1 country100 target enrollmentAugust 2015

Overview

Phase
Phase 2
Intervention
Prednisone
Conditions
Henoch-Schoenlein Purpura Nephritis
Sponsor
Nanjing Children's Hospital
Enrollment
100
Locations
1
Primary Endpoint
Disappearance of proteinuria
Last Updated
6 years ago

Overview

Brief Summary

This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN with mild proteinuria in children.

Detailed Description

Henoch-Schonlein purpura nephritis (HSPN) is one of the most common complications of Henoch-Schonlein purpura, and has become one of the main causes of chronic kidney disease in children. However, the diagnosis and treatment of HSPN is still based on the clinical experience, lacking of evidence-based support. This study is performed to explore the biological markers for early prediction of the prognosis and evaluate the efficacy and safety of various measures in the treatment of HSPN in children. The patients who are proved to get HSPN by renal biopsy will be randomized to receive either prednisone p.o. or angiotensin-converting enzyme inhibitor(ACEI) p.o. We will follow up them for about 2.5 years and compare the efficacy and safety of both measures by monitoring several indexes.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
July 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Nanjing Children's Hospital
Responsible Party
Principal Investigator
Principal Investigator

Aihua Zhang

Hospital vice president

Nanjing Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • Renal biopsy proved HSPN (ISKDC class II)
  • Proteinuria \< 25 mg/kg/d

Exclusion Criteria

  • The children with congenital diseases
  • Proteinuria≥25 mg/kg/d

Arms & Interventions

group 1

Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.

Intervention: Prednisone

group 2

Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)

Intervention: ACEI

Outcomes

Primary Outcomes

Disappearance of proteinuria

Time Frame: 30 months

The proteinuria is \< 150mg/d

Secondary Outcomes

  • Disappearance of hematuria(30 months)
  • Renal function(30 months)

Study Sites (1)

Loading locations...

Similar Trials